– Sample analysis and data collection ongoing – – Data expected during Q3 2025 – Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation to optimize health, today announced dosing has been completed for the PRIME (PReconditioning IMmunostimulatory Evaluation) Phase 1b clinical study of escalating doses of intravenously administered Gemini in patients with Stage 3 and 4 Chronic Kidney Disease (CKD). As planned, a total of 5 cohorts were enrolled at 3 clinics in the United States. Several study data sets are expected during Q3 2025: these will include safety parameters, changes in hematologic pa

Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), announced today that, on July 7, 2025, the Company will implement a 1-for-3 reverse split of its common stock following approval at its Special Meeting of Stockholders held on June 23, 2025. The reverse stock split will be effective as of the morning of July 7, 2025, and the Company's common stock will trade on a post-split basis at the beginning of trading on the same date under the existing trading symbol "REVB." The CUSIP number for the common stock following the reverse stock split will be 76135L705. The reverse stock split is intended to increase the market price per share of the Company's common stock to reg

Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today announced the closing of its previously announced public offering of 3,640,000 shares of its common stock (or common stock equivalents), together with warrants to purchase up to 14,560,000 shares of its common stock at an offering price to the public of $1.10 per share and associated warrant. The warrants will have an exercise price of $1.10 per share, are exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the warrants, and will expire five years

Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today announced the pricing of a public offering of 3,640,000 shares of its common stock (or common stock equivalents), together with warrants to purchase up to 14,560,000 shares of its common stock at an offering price to the public of $1.10 per share and associated warrant. The warrants will have an exercise price of $1.10 per share, are exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the warrants, and will expire five years following the initial

Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, announced the retirement of George F. Tidmarsh, MD, PhD from the Company's Board of Directors. "The team at Revelation wholeheartedly thanks Dr. Tidmarsh for his guidance and support over the past 5 years," said James Rolke, Chief Executive Officer of Revelation. "While he will be missed, we wish him the best of luck in his newest endeavor." "The Revelation team is dedicated to developing innovative therapies to improve the clinical outcomes for patients in need," said Dr. Tidmarsh. "I thank them for their passio

Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today reported its three months ended March 31, 2025 financial results. Corporate Highlights Announced a new indication for Gemini in severe burn patients Released data showing Gemini priming attenuated inflammation in peripheral blood mononuclear cells Completed dosing of first patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients "While we continue to expand the pipeline here at Revelation, we are excited to continue our collaboration with Vanderbilt and Dr. Bohannon in the area of severe bu

- This new indication is another step to unlock the full potential of the Gemini Platform - Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, announced a new target indication for Gemini for the prevention of infection in severe burn patients requiring hospitalization (the GEM-PBI program). The use of Gemini for the prevention of infection in severe burn patients, as well as the prevention of infection post-surgery (the GEM-PSI program) are a part of the patent family Revelation previously licensed from Vanderbilt University. "We are very pleased to be collabora

– Observed response is excellent surrogate of the potential of Gemini in target indications – – Equivalent response anticipated in Phase 1b study CKD patients – Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, announced Gemini priming attenuates the inflammatory response in human peripheral blood mononuclear cells (PBMCs) exposed to clinically relevant promoter molecules of inflammation. Revelation anticipates demonstrating the same protective effect in patients treated with Gemini in its Phase 1b clinical study, which will provide evidence of the potential eff

Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, announced today that James Rolke Revelation's Chief Executive Officer, will participate in a fireside chat at the 37th Annual Roth Conference on Tuesday, March 18, 2025 at 10:00 a.m. PT in Dana Point, CA. The fireside chat will be webcast live here and available on our Investors section of Revelation Biosciences website, www.RevBiosciences.com, after the meeting. Investors who wish to schedule a meeting with Revelation's management during the conference should contact their Roth representative. About Revelation

Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today reported its three and twelve months ended December 31, 2024 financial results. Corporate Highlights Announced dosing of first patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients Announced start of its PRIME Phase 1b Clinical Study of Gemini in CKD Patients Announced FDA Acceptance of Gemini IND Received net proceeds of $3.7 million from the exercise of warrants in December 2024 "We made significant progress at the end of last year and hope to continue that pace in 2025," said James

4 - REVELATION BIOSCIENCES, INC. (0001810560) (Issuer)

4 - REVELATION BIOSCIENCES, INC. (0001810560) (Issuer)

4 - REVELATION BIOSCIENCES, INC. (0001810560) (Issuer)

4 - REVELATION BIOSCIENCES, INC. (0001810560) (Issuer)

4 - REVELATION BIOSCIENCES, INC. (0001810560) (Issuer)

4 - REVELATION BIOSCIENCES, INC. (0001810560) (Issuer)

4 - REVELATION BIOSCIENCES, INC. (0001810560) (Issuer)

4 - REVELATION BIOSCIENCES, INC. (0001810560) (Issuer)

4 - REVELATION BIOSCIENCES, INC. (0001810560) (Issuer)

3 - REVELATION BIOSCIENCES, INC. (0001810560) (Issuer)

Roth Capital initiated coverage of Revelation Biosciences with a rating of Buy and set a new price target of $12.00

8-K - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)

8-K - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)

DEF 14A - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)

8-K - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)

PRE 14A - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)

424B3 - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)

EFFECT - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)

8-K - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)

S-1/A - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)

S-1 - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)

Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, announced the retirement of George F. Tidmarsh, MD, PhD from the Company's Board of Directors. "The team at Revelation wholeheartedly thanks Dr. Tidmarsh for his guidance and support over the past 5 years," said James Rolke, Chief Executive Officer of Revelation. "While he will be missed, we wish him the best of luck in his newest endeavor." "The Revelation team is dedicated to developing innovative therapies to improve the clinical outcomes for patients in need," said Dr. Tidmarsh. "I thank them for their passio

– A vote for Proposal 2 saves the Company over $200,000 per year – Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the treatment of disease, wants to remind all shareholders to vote their proxies for the January 17, 2025 special meeting of stockholders. In particular, a vote for Proposal 2, the redomicile of the Company from Delaware to Nevada will save the Company at least $200,000.00 per year in franchise tax fees. All proposals in the proxy are important and the Board of Directors has suggested a vote for all proposals. Please vote by calling Advantage Pr

Revelation Biosciences Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, today announced the appointment of Lakhmir Chawla M.D. to the Company's Board of Directors (Board). "We are excited to welcome Dr. Chawla as an independent director to our Board," said James Rolke, Chief Executive Officer of Revelation. "Dr. Chawla brings decades of expertise and leadership in key areas such as nephrology, critical care medicine, drug development and strategic implementation. I am confident that he will provide valuable perspectives as we continue to execute our str

Revelation Biosciences Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, today announced that the Company has adjourned its 2023 Annual Meeting of Stockholders (the "Annual Meeting") originally scheduled to be held on June 9, 2023, to July 7, 2023, at 1:00 p.m., Eastern Time, or at such other time or such other date to which the meeting may be adjourned. On June 9, 2023, the Company called to order its Annual Meeting. At the Annual Meeting, there were not present in person or by proxy at least a majority of the Company's common stock outstanding as of th

Revelation Biosciences Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a life sciences company that is focused on the development of immunologic-based therapies for the prevention and treatment of disease, today announced it has appointed Julia Bohannon, Ph.D. and Antonio Hernandez, M.D. to its scientific advisory board. Dr. Hernandez and Dr. Bohannon are inventors of the phosphorylated hexaacyl disaccharide (PHAD) based technology licensed from Vanderbilt University, previously announced on October 6, 2022. Julia Bohannon, Ph.D. is an Associate Professor in the Department of Anesthesiology and the Department of Pathology, Microbiology and Immunology at Vanderbilt University Medical Ce

Revelation Biosciences Inc. (NASDAQ:REVB) (the "Company" or "Revelation") announced today that, on February 1, 2023, the Company will implement a 1-for-35 reverse split of its common stock following approval at its Special Meeting of Stockholders held on January 30, 2023. The reverse stock split will be effective as of the morning of February 1, 2023, and the Company's common stock will trade on a post-split basis at the beginning of trading on the same date under the existing trading symbol "REVB." The CUSIP number for the common stock following the reverse stock split will be 76135L 309. At the meeting, the stockholders also approved an increase in the authorized common stock to 500,000,0

Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today reported its three months ended March 31, 2025 financial results. Corporate Highlights Announced a new indication for Gemini in severe burn patients Released data showing Gemini priming attenuated inflammation in peripheral blood mononuclear cells Completed dosing of first patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients "While we continue to expand the pipeline here at Revelation, we are excited to continue our collaboration with Vanderbilt and Dr. Bohannon in the area of severe bu

Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today reported its three and twelve months ended December 31, 2024 financial results. Corporate Highlights Announced dosing of first patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients Announced start of its PRIME Phase 1b Clinical Study of Gemini in CKD Patients Announced FDA Acceptance of Gemini IND Received net proceeds of $3.7 million from the exercise of warrants in December 2024 "We made significant progress at the end of last year and hope to continue that pace in 2025," said James

Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage biopharmaceutical company focused on harnessing the power of trained immunity for the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system, today reported its three and nine months ended September 30, 2024 financial results. Corporate Highlights Completed GMP manufacture of Gemini clinical drug supply Received net proceeds of $3.8 million from the exercise of warrants in August 2024 Announced Gemini induces dose dependent significant increases in IL-10 in healthy volunteers "The Revelation team continues to make significan

Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage biopharmaceutical company focused on harnessing the power of trained immunity for the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system, today reported its three and six months ended June 30, 2024 financial results. Corporate Highlights Completed dosing of its first in human phase 1 clinical study of Gemini Announced positive phase 1 clinical data of Gemini met the primary safety endpoint and showed statistically significant biomarker activity "The Revelation team has worked hard in the first half of 2024 to continue

Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today reported its three months ended March 31, 2024 financial results. Results of Operations As of March 31, 2024, Revelation had $14.6 million in cash and cash equivalents, compared to $12.0 million as of December 31, 2023. The increase in cash and cash equivalents was primarily due to net cash received from financing activities, offset primarily by cash used for operating activities. Based on current operating plans and projections, Revelation believes that its curren

Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today reported its three and nine months ended September 30, 2023 financial results. Corporate Highlights Recently released biomarker data demonstrating the pharmacologic activity of Gemini in multiple preclinical studies including: Significant mobilization and upregulation of white blood cells including neutrophils, monocytes and lymphocytes. Significant upregulation of therapeutic cytokines including interleukin-10 (IL-10), neutrophil gelatinase associated lipocalin (NGAL) and

Revelation Biosciences Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, today reported its three and six months ended June 30, 2023 financial results. Results of Operations As of June 30, 2023, Revelation had $15.7 million in cash and cash equivalents, compared to $5.3 million as of December 31, 2022. The increase in cash and cash equivalents was primarily due to net cash received from financing activities, offset primarily by cash used for operating activities. Based on current operating plans and projections, Revelation believes that its current cas

Revelation Biosciences Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, today reported its three months ended March 31, 2023 financial results and highlighted recent corporate progress. Corporate Highlights Established strong scientific advisory team with extensive preclinical experience using PHAD to prevent disease. Initiated additional nonclinical studies to further study PHAD in treatment and prevention of CKD and AKI in order to inform future clinical study designs in patients. IND and clinical enabling studies under way for anticipated Ph

SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, today reported first quarter 2022 financial results and highlighted recent corporate progress. Recent Corporate Progress In January we completed our merger with Petra Acquisition, Inc. and started trading on the Nasdaq Capital Market.Also in January, we completed our $7.7 million PIPE financing.We anticipate completing enrollment in the Phase 1b allergen challenge and receiving top-line data from that study during the secon

-CLEAR Study enrollment ongoing top-line data expected 2H 2022- -Diagnostic partnering discussions ongoing- SAN DIEGO, April 06, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, today announced that it will host investor conference call on April 7, 2022 at 4:30 p.m. Eastern Time. The conference call can be accessed by dialing (877) 815-0146 for domestic callers and (631) 625-3219 for international callers. Please provide the operator with the passcode 1166664 to join the conference call. An

SC 13G/A - REVELATION BIOSCIENCES, INC. (0001810560) (Subject)

SC 13G - REVELATION BIOSCIENCES, INC. (0001810560) (Subject)

SC 13G - REVELATION BIOSCIENCES, INC. (0001810560) (Subject)

SC 13G - REVELATION BIOSCIENCES, INC. (0001810560) (Subject)

SC 13G - REVELATION BIOSCIENCES, INC. (0001810560) (Subject)

SC 13G/A - REVELATION BIOSCIENCES, INC. (0001810560) (Subject)

SC 13G/A - REVELATION BIOSCIENCES, INC. (0001810560) (Subject)

SC 13G/A - REVELATION BIOSCIENCES, INC. (0001810560) (Subject)

SC 13G - REVELATION BIOSCIENCES, INC. (0001810560) (Subject)

SC 13G/A - REVELATION BIOSCIENCES, INC. (0001810560) (Subject)